This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma
by Zacks Equity Research
Teva (TEVA) and partner Celltrion get FDA nod for approval of their biosimilar to Roche's Rituxan in three Non-Hodgkin's lymphoma indications.
Why Is Biogen (BIIB) Up 4.5% Since Last Earnings Report?
by Zacks Equity Research
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings trump estimates in Q3. Higher royalties and product sales aid a significant surge in year-over-year revenues.
5 Top Stocks to Make the Most of a Divided Congress
by Tirthankar Chakraborty
Gridlock in Washington bodes well for healthcare and defense stocks, which calls for investing in such a space for the time being.
Election Day 2018: Here Are the Winners & Losers
by Tirthankar Chakraborty
One of the most awaited midterm elections in American history is upon us. Let's thus look at the sectors most likely to be impacted by the election results.
Biotech ETFs in Focus on String of Q3 Earnings Beat
by Zacks Equity Research
Biotech ETFs draw attention post impressive Q3 results.
What's in the Cards for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
Impressive sales of AbbVie's (ABBV) key drugs, Humira, Imbruvica and Mavyret are expected to drive third-quarter sales.
Top Research Reports for McDonald's, Thermo Fisher & Caterpillar
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), Thermo Fisher (TMO) and Caterpillar (CAT).
Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod
by Zacks Equity Research
Earnings releases and key data-read outs were the key developments in the biotech sector last week.
Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their third-quarter results on Oct 25. Let???s take a look at how these companies are poised ahead of their earnings release.
Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook
by Zacks Equity Research
Alkermes (ALKS) surpasses earnings and sales expectations in the third quarter of 2018 and raises its financial guidance for 2018.
Biogen (BIIB) Q3 Earnings & Sales Beat, Spinraza Shines
by Zacks Equity Research
Biogen beat estimates for both earnings and sales in the third quarter. Its newest drug Spinraza performs well in the quarter.
Biogen (BIIB) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
Biogen (BIIB) beat estimates both for earnings and sales in Q3. Its newest drug Spinraza performed well in the quarter.
BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?
by Zacks Equity Research
We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.
Biogen (BIIB) Q3 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
On the third-quarter call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.
Alkermes Boasts Strong Portfolio and Impressive Pipeline
by Zacks Equity Research
Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.
Biogen (BIIB) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Corium's (CORI) Shares Surge on Merger Agreement With Gurnet
by Zacks Equity Research
Corium International (CORI) announces merger agreement with Gurnet Point Capital. The deal values Corium at $12.50 per share in cash and will take the company private.
Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing
by Zacks Equity Research
Teva (TEVA) and partner Celltrion gets unanimous vote from an FDA advisory committee recommending approval of CT-P10, their proposed biosimilar to Roche's Rituxan.
Novartis Presents Data on Multiple Sclerosis Drug Gilenya
by Zacks Equity Research
Novartis (NVS) announces encouraging data from a late-stage trial, ASSESS, on multiple sclerosis drug, Gilenya, which further reinforces its efficacy in treating relapses.
The Zacks Analyst Blog Highlights: Altria, U.S. Bancorp, Biogen, Ecolab and HSBC
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Altria, U.S. Bancorp, Biogen, Ecolab and HSBC
Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
by Zacks Equity Research
Roche's (RHHBY) MS drug Ocrevus lowers disability progression over five years in relapsing/primary progressive multiple sclerosis with an early initiation of treatment.
Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status
by Zacks Equity Research
Data presentations by leading sector players take center stage this week.
Top Analyst Reports for Altria, U.S. Bancorp & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Altria (MO), U.S. Bancorp (USB) and Biogen (BIIB).